Xihong Biopharma successfully concluded its debut appearance at AMWC Southeast Asia 2025, one of the most influential medical aesthetics congresses in the ASEAN region. As a rising innovator in regenerative aesthetics, the company introduced its full portfolio of next-generation regenerative skin boosters and dermal fillers, including PLLA, CaHA, PCL and advanced composite formulas, marking an important milestone in expanding its presence across Southeast Asia and the global medical aesthetic market.


AMWC Southeast Asia welcomed more than 1,600 professional visitors from across Asia, the Middle East, Europe, Oceania, and the Americas. During the two-day exhibition, the Xihong booth became a focal point for aesthetic physicians, dermatologists, distributors, and research institutions seeking medical-device grade quality, next-generation regenerative injectable solutions. Our international business team conducted in-depth discussions with visitors from over 20 countries, exchanging insights on injection techniques, clinical experiences, regenerative mechanisms, and global market trends.
AMWC Southeast Asia served as a strategic platform for Xihong Biopharma to communicate its global capabilities, including:
These advantages reinforce Xihong’s position as a next-generation manufacturer capable of supporting worldwide market expansion in regenerative aesthetic injectables.
The positive response from international doctors and business partners confirms the strong global demand for high-performance regenerative injectables—particularly PLLA, CaHA, PCL, and hybrid skin boosters with hyaluronic acid that deliver natural, long-term biostimulation effects. Xihong Biopharma’s debut at AMWC Southeast Asia not only increased brand visibility but also built valuable clinical and commercial connections across emerging and developed markets.
As the company continues to accelerate CE registration and expand its global distribution network, Xihong Biopharma is committed to bringing safe, effective, and scientifically advanced regenerative products to more practitioners and patients around the world.